Patents Assigned to Windtree Therapeutics, Inc.
-
Publication number: 20230293548Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: ApplicationFiled: January 6, 2023Publication date: September 21, 2023Applicant: Windtree Therapeutics, Inc.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Patent number: 11583540Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: GrantFiled: November 2, 2021Date of Patent: February 21, 2023Assignee: WINDTREE THERAPEUTICS, INC.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Publication number: 20230009312Abstract: Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the disclosed compounds are derivatives of androstane having the formula (I). Also disclosed herein are pharmaceutical compositions comprising one or more of the compounds of formula (I) for use for the treatment of heart failure.Type: ApplicationFiled: October 8, 2020Publication date: January 12, 2023Applicant: Windtree Therapeutics, Inc.Inventors: Alberto CERRI, Patrizia FERRARI, Mara FERRANDI, Paolo BARASSI, Giusseppe BIANCHI, Shih-Che HSU, Francesco PERI, Antonio ZAZA, Marcella ROCCHETTI, Andrea LURAGHI, Eleonora TORRE, Carlotta RONCHI
-
Publication number: 20220054502Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: ApplicationFiled: November 2, 2021Publication date: February 24, 2022Applicant: Windtree Therapeutics, Inc.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Patent number: 11197869Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: GrantFiled: April 16, 2021Date of Patent: December 14, 2021Assignee: Windtree Therapeutics, Inc.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Publication number: 20210252017Abstract: Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.Type: ApplicationFiled: April 16, 2021Publication date: August 19, 2021Applicant: Windtree Therapeutics, Inc.Inventors: Giuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
-
Patent number: 9592361Abstract: An adaptor for delivering an aerosolized active agent to a patient with concomitant positive pressure ventilation includes an aerosol flow channel having an aerosol inlet port and a patient interface port, and defining an aerosol flow path from the aerosol inlet port to and through the patient interface port; and a ventilation gas flow channel in fluid communication with the aerosol flow channel and having a gas inlet port and a gas outlet port, and defining a ventilation gas flow path from the gas inlet port to and through the gas outlet port, wherein the ventilation gas flow path is at least partially offset from the aerosol flow path and at least partially encircles the aerosol flow path. Systems and methods for delivering an aerosolized active agent to a patient with concomitant positive pressure ventilation incorporate the adaptor.Type: GrantFiled: March 17, 2009Date of Patent: March 14, 2017Assignee: WINDTREE THERAPEUTICS, INC.Inventors: Jan Mazela, Christopher Henderson
-
Patent number: 9554999Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described.Type: GrantFiled: March 28, 2013Date of Patent: January 31, 2017Assignee: Windtree Therapeutics, Inc.Inventors: Sergio Cesco-Cancian, Thomas Hoy, Edward H. Trappler, Michael S. Thomas
-
Patent number: 9352114Abstract: An adaptor for delivering an aerosolized active agent to a patient with concomitant positive pressure ventilation includes an aerosol flow channel having an aerosol inlet port and a patient interface port, and defining an aerosol flow path from the aerosol inlet port to and through the patient interface port; and a ventilation gas flow channel in fluid communication with the aerosol flow channel and having a gas inlet port and a gas outlet port, and defining a ventilation gas flow path from the gas inlet port to and through the gas outlet port, wherein the ventilation gas flow path is at least partially offset from the aerosol flow path and at least partially encircles the aerosol flow path. Systems and methods for delivering an aerosolized active agent to a patient with concomitant positive pressure ventilation incorporate the adaptor.Type: GrantFiled: February 13, 2014Date of Patent: May 31, 2016Assignee: Windtree Therapeutics, Inc.Inventors: Jan Mazela, Christopher Henderson